With globally at least 30 million of cases per year, sepsis is a major health threat for which a specific adjunctive sepsis therapy beyond antimicrobial treatment, surgical source control and supportive intensive care measure is still missing.
https://european-biotechnology.com/wp-content/uploads/2024/04/EBM_Spring_16_Garlich_von_Essen_01.jpg450800h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-10 14:44:002016-10-10 14:44:00Why new approaches that target sepsis need support
Roche is making up lost ground in immuno-oncology. The Swiss company’s PD-L1 directed immunotherapy atezolizumab is more effective in combatting lung cancer than standard chemotherapy.
Well, those bloody idiots in the UK managed to do it talk themselves from decades of hysteria about straight bananas (entirely fabricated by one B Johnson during his time as a journalist in Brussels) into actually voting to leave.
https://european-biotechnology.com/wp-content/uploads/2024/04/claire-skentelbery.jpg450800h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-09 13:46:002016-10-09 13:46:00In the Brexshit
With about 38,000 attendees and 2,500 exhibitors, CPhI worldwide in Barcelona has broken another record. Personalised 3D printed pills and hypothesis generation using big data were only two trends reported.
Dublin-based protein immunotherapy developer Prothena has appointed Gene Kinney as its new President and Chief Executive Officer. Kinney has also been appointed to Prothena’s Board of Directors.
https://european-biotechnology.com/wp-content/uploads/2024/04/gene-kinney.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-06 10:17:102016-10-06 10:17:10Prothena: Filling in for a friend
The fate of the bioeconomy in Europe remains undecided. The evaluation of the European Commission’s bioeconomy strategy plus action plan has been delayed.
Danish insulin maker Novo Nordisk tries to relieve financial pressure by laying off 1,000 staff. The step was necessary due to challenges on the US market, the company said.
Swedish immuno-oncology play Immunicum AB has appointed Carlos de Sousa as its new CEO. Most recently, de Sousa worked as Chief Business Offer at Danish Zealand Pharma.
https://european-biotechnology.com/wp-content/uploads/2024/04/carlos-de-sousa.jpg297264h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-09-30 13:12:082016-09-30 13:12:08Immunicum: Doctor takes the lead
Why new approaches that target sepsis need support
OpinionWith globally at least 30 million of cases per year, sepsis is a major health threat for which a specific adjunctive sepsis therapy beyond antimicrobial treatment, surgical source control and supportive intensive care measure is still missing.
Roche’s NSLC mAb outperforms chemo
Latest NewsRoche is making up lost ground in immuno-oncology. The Swiss company’s PD-L1 directed immunotherapy atezolizumab is more effective in combatting lung cancer than standard chemotherapy.
In the Brexshit
OpinionWell, those bloody idiots in the UK managed to do it talk themselves from decades of hysteria about straight bananas (entirely fabricated by one B Johnson during his time as a journalist in Brussels) into actually voting to leave.
Synvina: BASF and Avantium join forces
Latest NewsThe new joint venture Synvina is positioned in the market for drop-in bioplastics with advanced product characteristics.
CPhI sheds light on future markets
Latest NewsWith about 38,000 attendees and 2,500 exhibitors, CPhI worldwide in Barcelona has broken another record. Personalised 3D printed pills and hypothesis generation using big data were only two trends reported.
Prothena: Filling in for a friend
AppointmentsEC delays bioeconomy strategy review
Latest NewsThe fate of the bioeconomy in Europe remains undecided. The evaluation of the European Commission’s bioeconomy strategy plus action plan has been delayed.
Apeiron licences neuroblastoma antibody
Latest NewsAustrian Apeiron Biologics has outlicensed the global marketing rights for its neuroblastoma antibody dinutuximab beta to British Eusa Pharma.
Diabetes giant cuts jobs
Latest NewsDanish insulin maker Novo Nordisk tries to relieve financial pressure by laying off 1,000 staff. The step was necessary due to challenges on the US market, the company said.
Immunicum: Doctor takes the lead
AppointmentsSwedish immuno-oncology play Immunicum AB has appointed Carlos de Sousa as its new CEO. Most recently, de Sousa worked as Chief Business Offer at Danish Zealand Pharma.